Generics (U.K.) Ltd & ors (claimants/respondents) v Astrazeneca AB (defendant/appellant)
Wednesday 25 – Thursday 26 June 2025
This is an appeal against the order of Michael Tappin KC (sitting as a Deputy High Ccourt Judge) dated 28 April 2025 that declared that the patent was at all material times invalid.
In the proceedings, the Claimants sought declarations that supplementary protection certificates were invalid and orders for their revocation, as well as a declaration that European Patent, which was the basic patent on which the SPCs were granted, was invalid.
The Patent was originally in the name of Bristol-Myers Squibb Co. but was assigned to the Defendant in 2014. The Patent claimed a priority date of 20 May 2002 and expired on 14 May 2023. It claimed a compound known as dapagliflozin and its use in the manufacture of a medicament for, inter alia, treating diabetes.
View hearing:
Day 1
Day 2